• Aucun résultat trouvé

X-linked acro-gigantism (X-LAG) : A new form of infant-onset pituitary gigantism

N/A
N/A
Protected

Academic year: 2021

Partager "X-linked acro-gigantism (X-LAG) : A new form of infant-onset pituitary gigantism"

Copied!
1
0
0

Texte intégral

(1)

Endocrine Abstracts (2015) 37 S11.1 | DOI:10.1530/endoabs.37.S11.1

X-linked acro-gigantism (X-LAG): a new form of

infant-onset pituitary gigantism

Giampaolo Trivellin1, Adrian F. Daly2, Fabio R. Faucz1, Bo Yuan3, Liliya Rostomyan2, Darwin O. Larco4, Ivana Bjelobaba5, Letícia F. Leal1, Marie Helene Schernthaner-Reiter1, Aggeliki

Dimopoulos1, Prashant Chittiboina6, Catherine S. Choong7, Peter Kamenický8, T. John Wu4, Stefano Costanzi9, Benjamin Feldman10, Stanko S. Stojilkovic5, James R. Lupski3, Albert Beckers2 & Constantine A. Stratakis1

1Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics (PDEGEN)

and Pediatric Endocrinology Inter-institute Training Program, Eunice Kennedy Shriver National Institute, Bethesda, Maryland, USA; 2Department of Endocrinology and Clinical Genetics, Centre Hospitalier

Universitaire de Liège, University of Liège, Liège, Belgium; 3Department of Molecular and Human

Genetics, Baylor College of Medicine, Houston, Texas, USA; 4Department of Obstetrics and Gynecology,

Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; 5Section on Cellular

Signaling, Program in Developmental Neuroscience, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, Maryland, USA; 6Surgical

Neurology Branch, National Institute of Neurological Diseases and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland, USA; 7Department of Paediatric Endocrinology, Princess Margaret

Hospital for Children and School of Pediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia; 8Université Paris Sud 11, Faculté de Médecine, UMR-S693, Le

Kremlin-Bicêtre, France; 9Department of Chemistry and Center for Behavioral Neuroscience, American University,

Washington, District of Columbia, USA; 10Program in Genomics of Differentiation (PGD), Eunice Kennedy

Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, Maryland, USA.

Introduction: Pituitary gigantism is a rare disorder caused by GH-secreting lesions. Aim: We studied gigantism for genetic defects.

Methods: We performed genome-wide analyses in 46 patients with gigantism and 248 patients with acromegaly.

Results: We detected a novel microduplication at chromosome Xq26.3 in two unrelated kindreds and 13 sporadic cases de novo. All patients had disease onset before five years of age and presented with mixed GH/prolactin-secreting macroadenomas and/or hyperplasia. All sporadic cases harbored non-recurrent duplications, whereas familial cases inherited the duplications from their mothers. Breakpoint junctions revealed microhomology, suggesting a replicative mechanism for their formation. Patients shared a common duplicated region of ~500 kb containing four protein-coding genes, of which only GPR101, a G-protein coupled receptor (GPCR) that activates cAMP signaling, was consistently over-expressed in patients’ pituitary lesions. Low GPR101 expression levels were seen in non-duplicated GH-secreting tumors and in most normal adult human tissues, including the pituitary. On the contrary, high expression was observed in human fetal pituitary. Adult pituitaries of both rhesus monkey and rat expressed GPR101 but in different cell types. In the developing zebrafish embryo a strong and brain-specific GPR101 staining (including in the hypothalamus and pituitary) was seen.

Conclusions: We describe a new genomic disorder caused by Xq26.3 microduplications (X-LAG for X-linked Acro-Gigantism) and characterized by early-onset gigantism. This syndrome is likely caused by

(2)

overexpression of GPR101, a dosage-sensitive GPCR that activates the cAMP pathway, whose mitogenic effects in pituitary somatotropes are well established. The brain is the major site of GPR101 expression across different species, although divergent species- and developmental stage-specific expression patterns are evident, especially concerning the pituitary. These differences might reflect the very different growth, development and maturation patterns among species. GPR101 may also be mutated in adult patients with acromegaly.

Disclosure: This work was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Références

Documents relatifs

Il n'y a pas de différences statistiquement significatives entre les deux tests du group de kata Il n'y a aucune différence entre les deux pré tests des deux groupes (expérimental

Recognizing that significant improvements in health of the newborn in all countries could be achieved by integrating safe motherhood activities with appropriate care of the

(1) to train those providing maternal and child health care in the principles and techniques of risk screening during pregnancy, clean and safe delivery, resuscitation, thermal

The documents and information collected should concern any key issue having some bearing on child health and development in the country, such as the constitution, existing

The safe motherhood programme could make a greater contribution to reducing maternal morbidity/mortality by: (a) strengthening the early recognition in the community of

Within the directorate there is a primary oral heaIth care department that identifies oral health problems and plans oraI health programmes including those on health

Multiple studies of PCB exposure and effects have been carried out in human populations, several of which raise concern that environmental levels of PCBs may reduce

Ten percent of BWS patients display an imprinting defect at the IGF2-H19 domain (aberrant GOM at the maternal copy of the ICR), which results in silencing of the maternal H19 gene and